Shell Asset Management Co. decreased its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Rating) by 13.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,031 shares of the biopharmaceutical company’s stock after selling 3,298 shares during the quarter. Shell Asset Management Co.’s holdings in Xenon Pharmaceuticals were worth $673,000 as of its most recent SEC filing.
Other institutional investors have also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. purchased a new position in shares of Xenon Pharmaceuticals during the 4th quarter worth $1,628,000. Brown Advisory Inc. purchased a new stake in Xenon Pharmaceuticals in the fourth quarter valued at approximately $403,000. Qube Research & Technologies Ltd purchased a new stake in Xenon Pharmaceuticals in the fourth quarter valued at approximately $447,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Xenon Pharmaceuticals by 127.7% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,565 shares of the biopharmaceutical company’s stock worth $299,000 after purchasing an additional 5,364 shares during the last quarter. Finally, New York State Common Retirement Fund purchased a new stake in shares of Xenon Pharmaceuticals during the fourth quarter worth approximately $253,000.
Xenon Pharmaceuticals Stock Performance
Shares of NASDAQ:XENE opened at $31.68 on Tuesday. The company has a market cap of $1.68 billion, a P/E ratio of -17.70 and a beta of 1.53. Xenon Pharmaceuticals Inc. has a one year low of $14.65 and a one year high of $36.42. The business’s 50-day simple moving average is $30.78 and its 200 day simple moving average is $30.51.
Wall Street Analyst Weigh In
Several research firms have weighed in on XENE. StockNews.com raised Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, July 27th. Wedbush decreased their price objective on Xenon Pharmaceuticals from $47.00 to $41.00 and set an “outperform” rating on the stock in a research note on Monday, June 27th. Finally, JPMorgan Chase & Co. initiated coverage on Xenon Pharmaceuticals in a research note on Thursday, July 21st. They set an “overweight” rating and a $55.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $45.33.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.
Featured Stories
- Get a free copy of the StockNews.com research report on Xenon Pharmaceuticals (XENE)
- MarketBeat Podcast: Find Investing Opportunities For The Rest of 2022
- The Colgate-Palmolive Growth Outlook BrightensÂ
- Deep Value High Yield Newell Brands Is Ready To BottomÂ
- These Stocks Outperformed Last Time There Was A Recession
- Does Rivian’s Stock Still Have A Future?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
